Oligonucleotide Synthesis Market to Grow with a CAGR of 13.30% through 2028
Advancements in genomic research and RNA-based therapeutics are driving
the growth of Oligonucleotide Synthesis market in the forecast period
2024-2028.
According to TechSci Research report, “Oligonucleotide Synthesis
Market – Global Industry Size, Share, Trends, Competition Forecast &
Opportunities, 2028”, the Global Oligonucleotide Synthesis Market stood
at USD 4.03 billion in 2022 and is anticipated to grow with a CAGR of 13.30 % in
the forecast period, 2024-2028. The Oligonucleotide Synthesis market stands at
the forefront of the life sciences and biotechnology sectors, offering
essential genetic materials that underpin a wide array of applications. In
recent years, this market has experienced remarkable growth, driven by various
factors that include advancements in genomic research, the rise of RNA-based
therapeutics, and the increasing demand for precision medicine. Yet, like any
thriving industry, it faces a set of challenges and disruptions, including the
profound impact of the COVID-19 pandemic.
One of the primary
drivers of the Oligonucleotide Synthesis market is the continuous advancement
in genomic research. The decoding of entire genomes, precision medicine, and
the quest for personalized healthcare all rely heavily on oligonucleotides for
genetic analysis, molecular diagnostics, and gene editing. As researchers delve
deeper into understanding the genetic basis of diseases and the complexities of
human biology, the demand for customized oligonucleotides continues to surge.
RNA-based
therapeutics represent another significant driver. The development of messenger
RNA (mRNA) vaccines, gene therapies, and RNA interference (RNAi) treatments has
fueled the demand for tailor-made RNA molecules. Oligonucleotide synthesis
plays a pivotal role in producing high-quality, synthetic RNA sequences,
enabling these groundbreaking therapies that hold the promise of treating
various diseases with precision and efficacy. The rise of gene editing, notably
CRISPR-Cas9 technology, is yet another driving force. Researchers and biotech
companies rely on precisely engineered oligonucleotides to target specific
genetic sequences, enabling breakthroughs in genetics and biotechnology. This
transformative technology has applications in agriculture, medicine, and
various industries, driving demand for custom oligonucleotide synthesis
services. Several prominent trends are shaping the Oligonucleotide Synthesis
market. Firstly, customization and modification of oligonucleotides are on the
rise. Researchers seek chemically modified oligos to enhance stability,
specificity, and therapeutic effectiveness. This trend aligns with the
increasing adoption of precision medicine, where treatments are tailored to an
individual's genetic makeup.
Automation and
high-throughput technologies are also gaining traction. These advancements
streamline the production of oligonucleotides, reducing costs and turnaround
times. As the market grows and demand surges, the ability to efficiently scale
up production becomes paramount. Single-cell genomics is reshaping research,
with the need for specialized oligonucleotide probes and primers for studying
individual cells within complex tissues. This trend has profound implications
for cancer research, immunology, and more. In the diagnostic realm, the
development of oligonucleotide-based tests for early disease detection and
monitoring treatment responses is a growing trend. As precision medicine
becomes more prevalent, the demand for diagnostic oligonucleotides is set to rise.
While the
Oligonucleotide Synthesis market thrives, it is not without its challenges.
Cost constraints are a primary concern, especially for long or chemically
modified oligonucleotides. Achieving cost-effectiveness without compromising
quality remains an ongoing challenge for both researchers and manufacturers. Efficiency
and scalability are crucial for meeting the increasing demand for
oligonucleotides. Researchers and companies must balance efficiency in
production processes with scalability to accommodate the growing market. Stringent
regulatory requirements pose another challenge, especially in the context of
oligonucleotide-based therapeutics. Companies must navigate complex regulatory
landscapes to ensure compliance and safety. Quality control and consistency are
vital in oligonucleotide production, given their diverse applications.
Maintaining high-quality standards across batches remains a challenge.
The COVID-19
pandemic had both positive and negative effects on the Oligonucleotide
Synthesis market. On one hand, the development of mRNA vaccines for COVID-19
showcased the market's potential. Oligonucleotide synthesis played a pivotal
role in producing the synthetic RNA sequences used in these vaccines,
highlighting the market's importance in public health emergencies. However, the
pandemic also disrupted supply chains and led to delays in research projects
and clinical trials. The closure of laboratories and disruptions in logistics
temporarily hindered the market's growth. Nonetheless, the pandemic underscored
the critical role of oligonucleotide synthesis in responding to global health
crises, leading to increased investments and attention on the industry.
Browse over XX market data Figures spread through 185 Pages and an
in-depth TOC on
"Global Oligonucleotide Synthesis Market.”
The Global Oligonucleotide
Synthesis Market is segmented into product type, application, end user, regional
distribution, and company.
Based on application,
the Services segment has emerged as the predominant market leader in the Oligonucleotide
Synthesis market. The Services segment has firmly established itself as the predominant
market leader in the Oligonucleotide Synthesis market due to several compelling
reasons. Oligonucleotide synthesis is a specialized and intricate process that
necessitates precision, expertise, and access to cutting-edge technology. As a
result, many research institutions, pharmaceutical companies, and biotech firms
prefer to outsource this crucial component of their projects to specialized
service providers. These oligonucleotide synthesis service providers offer a
wide range of benefits, including access to state-of-the-art equipment, highly
skilled personnel, and cost-effective production processes. Moreover, the
rapidly evolving landscape of genomics research and therapeutic development
demands flexibility and scalability, which services providers are uniquely
equipped to offer. Researchers and companies can readily access custom-designed
oligonucleotides in the required quantities without the burden of maintaining
in-house synthesis capabilities, thus streamlining their operations and reducing
time-to-market. The Services segment also thrives on its ability to provide
tailored solutions, including chemically modified oligonucleotides,
high-throughput synthesis, and specialized purification methods. These
capabilities are essential for applications such as RNA-based therapeutics,
gene editing, and diagnostics, where precision and quality are paramount. Additionally,
the Oligonucleotide Synthesis market's regulatory landscape is becoming
increasingly complex, particularly in the context of therapeutic applications.
Outsourcing to established service providers ensures adherence to stringent
quality control standards and regulatory compliance, which can be challenging
to maintain in-house.
Based on region, North
America region anticipated to experience significant growth during the forecast
period in the Oligonucleotide Synthesis market. The North America region is
poised for significant growth in the Oligonucleotide Synthesis market during
the forecast period, primarily due to a combination of key factors that create
a conducive environment for market expansion. Firstly, North America boasts a
robust and highly innovative pharmaceutical and biotechnology industry,
particularly in the United States. This industry has been a pioneer in adopting
cutting-edge technologies, including genomics and RNA-based therapeutics, both
of which rely heavily on oligonucleotide synthesis. The presence of numerous
leading biotech companies and research institutions fosters a thriving
ecosystem for innovation, research collaborations, and market growth. Secondly,
the region benefits from substantial investments in healthcare and life
sciences research. Government funding, private investments, and venture capital
have flowed into North America, supporting groundbreaking genomic studies, gene
therapies, and RNA-based therapeutics. These financial backing fuels the demand
for oligonucleotide synthesis services, as researchers seek reliable and
specialized partners for their projects. Furthermore, the regulatory landscape
in North America is favorable to oligonucleotide-based therapeutics. Regulatory
agencies like the U.S. Food and Drug Administration (FDA) have established
clear pathways and guidelines for the approval of oligonucleotide drugs and
therapies. This regulatory predictability instills confidence in the market,
facilitating the development and commercialization of novel products. Moreover,
North America's strong emphasis on precision medicine and personalized
healthcare aligns with the trend towards tailored therapies that use
custom-designed oligonucleotides to target specific genetic markers or
mutations. This alignment of market demand with regional healthcare priorities
positions North America as a prominent growth driver. Lastly, the region's
well-established infrastructure and logistics networks ensure efficient supply
chains and timely delivery of oligonucleotides, further enhancing its
competitive advantage.
Major companies operating in Global Oligonucleotide Synthesis Market
are:
- Thermo
Fisher Scientific Inc
- Agilent Technologies,
Inc.
- Merck KGaA
- BIO-Synthesis Inc
- Eurofins Scientific SE
- Danaher Corporation
- Agilent Technologies,
Inc.
- Biogen Inc.
- Ionis Pharmaceuticals,
Inc.
- Sarepta Therapeutics,
Inc.
Download Free Sample Report
Customers can also request for 10% free customization on this report.
“The Oligonucleotide Synthesis market, driven by innovation and a surge
in genomics research and RNA-based therapies, features prominent companies such
as Integrated DNA Technologies (IDT), Eurofins Genomics, Thermo Fisher
Scientific, and Merck KGaA. These industry leaders provide a spectrum of
services, from custom oligonucleotide synthesis and modification to
high-throughput production, catering to the diverse needs of researchers and
pharmaceutical firms. With North America leading in market dominance due to its
thriving biotech ecosystem and regulatory support, these companies are at the
forefront of delivering high-quality, precise oligonucleotides critical for
genomics research, gene editing, RNA therapeutics, and diagnostic applications.
Their expertise, scalability, and commitment to innovation continue to shape
the dynamic landscape of this pivotal industry.” said Mr. Karan Chechi,
Research Director with TechSci Research, a research-based management consulting
firm.
“Oligonucleotide Synthesis
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
2018-2028 Segmented By Product Type (Synthesized Oligonucleotide Products,
Reagents, Equipment, and Services), By Application (Research, Therapeutics, and
Diagnostics), By End User (Academic Research Institutes, Pharmaceutical and
Biotechnology Companies, and Hospital and Diagnostic Laboratories), By Region
and Competition”, has
evaluated the future growth potential of Global Oligonucleotide Synthesis
Market and provides statistics & information on market size, structure and
future market growth. The report intends to provide cutting-edge market
intelligence and help decision makers take sound investment decisions. Besides,
the report also identifies and analyzes the emerging trends along with
essential drivers, challenges, and opportunities in Global Oligonucleotide
Synthesis Market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com